作者: J. Otsuka , T. Okuda , A. Sekizawa , S. Amemiya , H. Saito
DOI: 10.1111/J.1048-891X.2004.014305.X
关键词: Pathology 、 Point mutation 、 Tumor marker 、 Mutation 、 Medicine 、 DNA 、 COLD-PCR 、 Germline mutation 、 Ovarian cancer 、 Cancer
摘要: Mutation of p53 is one the most common genetic abnormalities detected in up to 81% cases ovarian cancer. To evaluate use plasma DNA analysis as a method for somatic mutation screening, we measured presence mutations isolated from and cancer tissue patients with We analyzed (exons 5-8). Of 27 cancer, 12 (44%) had tissue. In two (16.7%), identical were their preoperative plasma. our follow-up plasma, mutant was undetectable after surgery. case, re-surfaced 16 months surgery, patient died 2 later. have shown that tumor-derived can be some particularly those more advanced stage.